[go: up one dir, main page]

WO2009062128A3 - Combination drug therapy for the treatment of cancer - Google Patents

Combination drug therapy for the treatment of cancer Download PDF

Info

Publication number
WO2009062128A3
WO2009062128A3 PCT/US2008/082924 US2008082924W WO2009062128A3 WO 2009062128 A3 WO2009062128 A3 WO 2009062128A3 US 2008082924 W US2008082924 W US 2008082924W WO 2009062128 A3 WO2009062128 A3 WO 2009062128A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug therapy
cancer
combination drug
combination
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/082924
Other languages
French (fr)
Other versions
WO2009062128A2 (en
Inventor
Karen E. Pollok
Lindsey D. Mayo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of WO2009062128A2 publication Critical patent/WO2009062128A2/en
Publication of WO2009062128A3 publication Critical patent/WO2009062128A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A combination of drugs was used to kill or inhibit the growth of cancer cells. The combination drug therapy includes administering to a human or animal patient diagnosed with cancer at least one drug that inhibits the activity of an intracellular protein that repairs alkylated DNA and a drug that inhibits the interaction between Hdm2 and p53. The combination drug therapy is useful in the treatment of tumors including some tumors that have become drug resistant. In some instances the combination drug therapy allows the drugs to be administered to a patient at therapeutically effective submyeloablative levels. Still another aspect provides a combination drug therapy that includes administering to a cancer patient a therapeutically effective dose of at least one compound that alkylates DNA, at least one compound that inhibits at least one DNA repair protein and at least one compound that prolongs the half-life of p53 by inhibiting the interaction of p53 with HDM2.
PCT/US2008/082924 2007-11-08 2008-11-08 Combination drug therapy for the treatment of cancer Ceased WO2009062128A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98652507P 2007-11-08 2007-11-08
US60/986,525 2007-11-08

Publications (2)

Publication Number Publication Date
WO2009062128A2 WO2009062128A2 (en) 2009-05-14
WO2009062128A3 true WO2009062128A3 (en) 2009-09-17

Family

ID=40626463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/082924 Ceased WO2009062128A2 (en) 2007-11-08 2008-11-08 Combination drug therapy for the treatment of cancer

Country Status (1)

Country Link
WO (1) WO2009062128A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6449849B2 (en) 2013-04-05 2019-01-09 バイオマーク・ファーマシューティカルズ・リミテッド Inhibitor of metastasis
CN104174020A (en) * 2013-05-21 2014-12-03 北京大学 Application of human derived protein hCINAP and its gene in development of anticancer drugs
WO2025098488A1 (en) * 2023-11-09 2025-05-15 深圳艾欣达伟医药科技有限公司 Drug upregulating p53 protein expression or activating p53 function and dna alkylating agent used in combination for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211757A1 (en) * 2005-02-22 2006-09-21 Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211757A1 (en) * 2005-02-22 2006-09-21 Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAI ET AL.: "Mitochondrial Targeting of Human o6-Methylguanine DNA Methyltransferase Protects Against Cell Killing by Chemotherapeutic Alkylating Agent.", CANCER RESEARCH, vol. 65, no. 8, 2005, pages 3319 - 3327 *
CAIMCROSS ET AL.: "Myeloablative Chemotherapy for Recurrent Aggressive Oligodendroglioma.", NEURO-ONCOLOGY, vol. 2, April 2000 (2000-04-01), pages 114 - 119 *
CHANG ET AL.: "Differential Mechanisms in the Regulation of Endogenous Levels of Thrombopoletln and Interleukin-11 Durlng Thrombocytopenla: Insight Into the Regulation of Platelet Production.", BLOOD, vol. 88, 1996, pages 3354 - 3362 *
DATABASE GENBANK 1 October 2007 (2007-10-01), "Chain A, Human O6-Alkylguanine-Dna Alkyltransferase Covalently Crosslinked To DNA", XP003025507, retrieved from http:llwww.ncbi.nlm.nih.gov/sviewer/viewer.fcgi?51247521:PROT:5241323 Database accession no. 1T39_A *
MCKEOWN ET AL.: "DNA Repair: Therapeutic Implications.", BRIT. J. RADIOL., vol. 79, 2006, pages 91 - 93 *
UENO ET AL.: "Modulation of Chemotherapy Resistance in Regional Therapy: A Novel Therapeutic Approach to Advanced Extremity Melanoma.", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 3, 2006, pages 731 - 738 *

Also Published As

Publication number Publication date
WO2009062128A2 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
EP1778215B1 (en) Anticancer effect enhancer
American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Cardiac Rhythm Management Devices Practice advisory for the perioperative management of patients with cardiac rhythm management devices: pacemakers and implantable cardioverter-defibrillators: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Cardiac Rhythm Management Devices
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
ECSP056076A (en) SUPPLY SYSTEM FOR DRUG AND CELL THERAPY
BRPI0608175A2 (en) method of eliminating heterogeneous or mixed cell population in tumors as well as maytansinoid compounds
AU2013308465B2 (en) Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
BR112013010829A2 (en) intravenous pharmaceutical composition to provide pain and / or inflammation relief, use and method thereof
CY1116544T1 (en) USE OF LYSOSOMIC ACID FATTY FOR THE TREATMENT OF LYSOSOMIC ACID OIL DEFICIENCY IN PATIENTS
BRPI0519656A2 (en) combination therapy comprising telmisartan and hydrochlorothiazide
DE602004016376D1 (en) COMBINATION OF ET-743 WITH 5-FLUOROURACIL PRO DRUGS FOR THE TREATMENT OF CANCER
BRPI0510895A (en) 10-propargyl-10-deazaaminopterin pharmaceutical formulation for t-cell lymphoma treatment
RU2012108439A (en) METHODS FOR TREATING TUMORS OF THE BRAIN
Holliday et al. Methotrexate: role of treatment in skin disease
WO2009062128A3 (en) Combination drug therapy for the treatment of cancer
CY1118486T1 (en) LAPATINIBE FOR CANCER TREATMENT
AR079000A1 (en) ANTI-BANK THERAPY AIMED AT CANCEROSA MOTHER RESISTANT DRUG CELLS
Hu et al. Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
Blakley et al. Differences in Ototoxicity across Species.
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
Murata et al. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole
Singh et al. Thymoma: Diagnosis and treatment
MX2010006310A (en) O-desmethyl-venlafaxine for treating major depressive disorder.
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
ES2543364B1 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT, AN ADJUSING AGENT AND AN ANTI-NURETIC ANALGESIC, WITH ANTI-BIOCEPTIVE EFFECT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08847359

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08847359

Country of ref document: EP

Kind code of ref document: A2